Panbela announces validation of european patent in uk, italy, germany, france, and spain for claims of a novel process for the production of sbp-101

Minneapolis, oct. 31, 2023 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced validation for the european patent 2019213664 titled "methods for producing (6s,15s)-3,8,13,18- tetraazaicosane-6,15-diol" in the united kingdom, italy, germany, france, and spain. this patent, developed in collaboration with syngene international ltd.
PBLA Ratings Summary
PBLA Quant Ranking